HUTCHMED (HCM) AI Stock Analysis

• Market Cap: $2.45B
• Dividend Yield: N/A
• Average Volume (3M): 48.41K
• Price to Earnings (P/E): 5.0
• Beta (1Y): 0.42
• Revenue Growth: -1.35%
• EPS Growth: N/A
• Country: US
• Employees: 1,811
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.01
• Shares Outstanding: 174,465,530
• 10 Day Avg. Volume: 34,563
• 30 Day Avg. Volume: 48,412
• PEG Ratio: <0.01
• Price to Book (P/B): 1.85
• Price to Sales (P/S): 4.16
• P/FCF Ratio: -28.96
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 4.06
• Enterprise Value/Gross Profit: 45.49
• Enterprise Value/Ebitda: -326.50
• 1Y Price Target: $20.00
• Price Target Upside: 41.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.31
• Revenue Forecast (FY): $637.63M

• Rating: 53 Neutral
• Price Target: $14.00 ▼(-1.06% Downside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is held back primarily by weakening operating performance and cash burn despite a strong, low-leverage balance sheet. Technicals also indicate a sustained downtrend. A low P/E provides some valuation support, but is tempered by concerns that recent earnings are less repeatable and not backed by cash flow.

Positive Factors

Low leverage balance sheet

Hutchmed's very low debt-to-equity (~0.08) provides durable financial flexibility to support multi-year R&D and late-stage trials. Low leverage reduces interest costs and refinancing risk, enabling the company to fund development or strategic collaborations without near-term balance-sheet strain.

Negative Factors

Negative cash generation

Material negative operating and free cash flow in 2025 indicates the business is consuming cash rather than generating it. Persistent cash burn increases reliance on external financing or partner milestones, raising execution risk for multi-year trials and potentially forcing trade-offs between R&D, commercialization and capital preservation.

HUTCHMED Business Overview & Revenue Model

Company Description

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The c...

Read more

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The c...

How the Company Makes Money

HUTCHMED generates revenue primarily through the commercialization of its proprietary drug products, including sales from its marketed therapies. Additionally, the company earns income through collaborations and partnerships with other pharmaceuti...

Read more

HUTCHMED generates revenue primarily through the commercialization of its proprietary drug products, including sales from its marketed therapies. Additionally, the company earns income through collaborations and partnerships with other pharmaceuti...

HUTCHMED Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	602.20M	549.96M	630.20M	838.00M	426.41M	356.13M
Gross Profit	53.76M	212.72M	281.32M	453.55M	115.31M	97.89M
EBITDA	-7.49M	-41.38M	14.11M	67.27M	-401.11M	-207.96M
Net Income	466.88M	458.12M	37.73M	100.78M	-360.83M	-194.65M
Balance Sheet
Total Assets	1.78B	1.75B	1.27B	1.28B	1.03B	1.37B
Cash, Cash Equivalents and Short-Term Investments	1.36B	1.37B	836.11M	886.34M	631.00M	1.01B
Total Debt	93.44M	97.89M	89.82M	86.13M	27.01M	38.98M
Total Liabilities	534.02M	501.84M	502.34M	536.39M	392.57M	333.15M
Stockholders Equity	1.23B	1.24B	759.93M	730.54M	610.37M	986.89M
Cash Flow
Free Cash Flow	-49.66M	-79.01M	-17.44M	186.65M	-305.26M	-220.98M
Operating Cash Flow	-32.56M	-64.83M	497.00K	219.26M	-268.60M	-204.22M
Investing Cash Flow	-73.03M	-29.49M	-96.06M	-291.14M	296.59M	-306.32M
Financing Cash Flow	11.22M	7.86M	-30.67M	48.66M	-82.76M	650.03M

HUTCHMED Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 14.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HCM, the sentiment is Neutral. The current price of 14.15 is above the 20-day moving average (MA) of 14.04, below the 50-day MA of 14.69, and below the 200-day MA of 15.31, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 47.94 is Neutral, neither overbought nor oversold. The STOCH value of 45.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HCM.

HUTCHMED Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANIP	67 Neutral	$1.66B	14.40	15.55%	―	48.87%	―
SUPN	60 Neutral	$2.88B	-72.78	-0.01%	―	4.54%	-130.59%
AMRX	54 Neutral	$3.86B	54.80	-67.91%	―	9.50%	―
HCM	53 Neutral	$2.45B	4.99	41.91%	―	-1.35%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	48 Neutral	$1.33B	―	-35.16%	8.48%	-2.55%	66.00%
ALVO	42 Neutral	$1.04B	-117.81	-26.11%	―	55.38%	―